Last reviewed · How we verify
NCT03558373
The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant Recipients
trial testing Immunosuppressive in Kidney Transplant in 158 participants. Completed in 26 February 2020.
26 February 2020
Quick facts
| Lead sponsor | Chiesi Farmaceutici S.p.A. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 158 |
| Start date | 31 July 2018 |
| Primary completion | 26 February 2020 |
| Estimated completion | 26 February 2020 |
| Sites | 12 locations across Italy |
Drugs / interventions tested
- Immunosuppressive
Conditions studied
- Kidney Transplant — all drugs for Kidney Transplant →
Sponsor
Chiesi Farmaceutici S.p.A. — full company profile →
Who can join
18 and older, any sex, with Kidney Transplant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-adherence is widespread in the transplant community. Addressing issues associated with non-adherence remains a key challenge in transplantation, in part due to the difficulty in assessing its prevalence, as there is currently no 'gold standard' for use in routine clinical practice. The purpose of this study is to evaluate the non-adherence to immunosuppressive therapy, including tacrolimus once-daily, among Italian kidney transplant recipients receiving. Along with non-adherence evaluation, possible factors related to NA will be investigated (patient-related, condition/disease-related, therapy/treatment-related, etc.).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03558373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunosuppressive
Trials testing the same drug.
- NCT05808192 — De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal · completed
Other recruiting trials for Kidney Transplant
Currently open trials in the same condition.
- NCT07532382 — Personalized Stories for Pediatric Kidney Recipients · recruiting
- NCT07348458 — Kidney Protective Jacket · NA · recruiting
- NCT07333495 — A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-c · recruiting
- NCT06919003 — Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE · Phase 2 · recruiting
- NCT07205692 — Multimorbidity and Cardiovascular Risk Factors After Renal Transplant · recruiting
Other Chiesi Farmaceutici S.p.A. trials
Trials by the same sponsor.
- NCT07516951 — A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis · Phase 2 · not yet recruiting
- NCT07301736 — Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma · Phase 2 · recruiting
- NCT07163182 — Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and · Phase 1 · recruiting
- NCT06900816 — A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate C · Phase 2 · completed
- NCT06892756 — Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03558373 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chiesi Farmaceutici S.p.A.
- Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03558373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing